英威騰(002334.SZ):子公司預中標5680萬元深圳地鐵項目
格隆匯6月2日丨英威騰(002334.SZ)公佈,近日,公司的控股子公司深圳市英威騰交通技術有限公司(簡稱“交通公司”)參與了深圳地鐵6號線支線及其二期工程車輛電氣系統採購項目的公開招投標。
機電產品招標投標電子交易平台於2021年6月1日發佈了《深圳地鐵6號線支線及其二期工程車輛電氣系統採購項目評標結果公示公吿》,交通公司為深圳地鐵6號線支線及其二期工程車輛電氣系統採購項目第一中標候選人,預計中標金額為5680萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.